Regeneron Pharmaceuticals, Inc. (REGN) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1159823,
    "name": "Regeneron Pharmaceuticals, Inc.",
    "stock_name": "Regeneron Pharmaceuticals, Inc.",
    "full_name": "Regeneron Pharmaceuticals, Inc.",
    "name_url": "stocks-analysis/regeneron-pharmaceuticals-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "722.80",
    "chg": -19.2,
    "chgp": "-2.59%",
    "dir": -1,
    "prev_price": "742.00",
    "mcapval": "76,834.33",
    "mcap": "Large Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2305,
    "indexname": "S&P 500",
    "isin": "US75886F1075",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "2.13 M",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/regeneron-pharmaceuticals-inc-1159823-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Regeneron Pharmaceuticals Hits Day Low of $561 Amid Price Pressure",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/regeneron-pharmaceuticals-hits-day-low-of-561-amid-price-pressure-3608121",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/RegeneronPharma_priceRelatedfactors_3608121.png",
        "date": "2025-10-09 20:53:00",
        "description": "Regeneron Pharmaceuticals, Inc. faced a challenging trading session on October 8, 2025, with a notable stock price decline. Over the past week, the company has experienced a decrease, contrasting with the S&P 500's performance. Despite recent setbacks, Regeneron maintains a strong market position and demonstrates healthy long-term growth."
      },
      {
        "title": "Regeneron Pharmaceuticals Experiences Revision in Stock Evaluation Amid Market Challenges",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/regeneron-pharmaceuticals-technical-trend-shifts-from-mildly-bearish-to-sideways-amid-stock-volatility-3601171",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/RegeneronPharma_technicaldot_3601171.png",
        "date": "2025-10-07 20:15:14",
        "description": "Regeneron Pharmaceuticals, Inc. has recently revised its evaluation amid changing market conditions. The stock is currently priced at $585.48, with a notable 52-week range. Technical indicators show mixed trends, and the company has faced significant challenges, underperforming compared to the S&P 500 over the past year."
      },
      {
        "title": "Is Regeneron Pharmaceuticals, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-regeneron-pharmaceuticals-inc-technically-bullish-or-bearish-3593452",
        "imagepath": "",
        "date": "2025-10-06 11:58:28",
        "description": "As of 3 October 2025, the technical trend for Regeneron Pharmaceuticals, Inc. has changed from mildly bearish to sideways. The current technical stance is neutral, with mixed indicators influencing the outlook. The weekly MACD is mildly bullish, while the monthly MACD is bearish. The weekly RSI shows no signal, but the monthly RSI is bullish. Bollinger Bands indicate a bullish stance weekly but mildly bearish monthly. Daily moving averages are mildly bearish. The KST is bullish weekly but bearish monthly, and Dow Theory suggests a mildly bullish outlook for both weekly and monthly periods. \n\nIn terms of performance, Regeneron has underperformed the S&P 500 significantly over the longer term, with a year-to-date return of -15.77% compared to the S&P 500's 14.18%, and a one-year return of -40.86% versus 17.82% for the index...."
      },
      {
        "title": "Is Regeneron Pharmaceuticals, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-regeneron-pharmaceuticals-inc-technically-bullish-or-bearish-3591522",
        "imagepath": "",
        "date": "2025-10-05 11:43:18",
        "description": "As of 3 October 2025, the technical trend for Regeneron Pharmaceuticals, Inc. has changed from mildly bearish to sideways. The current stance is neutral, with mixed signals across different indicators. The weekly MACD is mildly bullish, while the monthly MACD is bearish. The RSI shows no signal on the weekly chart but is bullish on the monthly. The Bollinger Bands indicate a bullish trend weekly but mildly bearish monthly. Moving averages are mildly bearish on the daily timeframe. Dow Theory reflects a mildly bullish stance on both weekly and monthly charts. \n\nIn terms of performance, Regeneron has underperformed the S&P 500 significantly over the longer term, with a year-to-date return of -15.77% compared to the S&P 500's 14.18%, and a one-year return of -40.86% versus 17.82% for the index...."
      },
      {
        "title": "Regeneron Pharmaceuticals Hits Day Low Amid Price Pressure, Closing at $549.40",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/regeneron-pharmaceuticals-hits-day-low-amid-price-pressure-closing-at-54940-3574358",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/9/RegeneronPharma_priceRelatedfactors_3574358.png",
        "date": "2025-09-26 14:24:01",
        "description": "Regeneron Pharmaceuticals, Inc. faced a significant decline in stock value, contrasting with the broader market's performance. Over the past year, the company has experienced a substantial decrease, while maintaining strong management efficiency and healthy long-term growth in net sales, reflecting its position in the pharmaceuticals and biotechnology sector."
      },
      {
        "title": "Regeneron Pharmaceuticals Hits Day Low Amid Price Pressure at $565.53",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/regeneron-pharmaceuticals-hits-day-low-amid-price-pressure-at-56553-3565115",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/9/RegeneronPharma_priceRelatedfactors_3565115.png",
        "date": "2025-09-24 13:08:07",
        "description": "Regeneron Pharmaceuticals, Inc. faced a significant stock decline today, reaching an intraday low. Despite this, the company holds a strong market position with a substantial market capitalization and efficient management, evidenced by a notable return on equity. Long-term growth remains positive, supported by healthy net sales increases."
      },
      {
        "title": "Is Regeneron Pharmaceuticals, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-regeneron-pharmaceuticals-inc-technically-bullish-or-bearish-3545201",
        "imagepath": "",
        "date": "2025-09-20 19:06:07",
        "description": "As of 25 August 2025, the technical trend for Regeneron Pharmaceuticals, Inc. has changed from sideways to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD is bearish. The RSI shows no signal on the weekly chart but is bullish on the monthly. Bollinger Bands are bullish weekly but mildly bearish monthly. Daily moving averages are mildly bearish, and the KST is bullish weekly but bearish monthly. Dow Theory indicates a mildly bearish trend on the weekly and no trend on the monthly.\n\nIn terms of performance, Regeneron has underperformed the S&P 500 significantly over the past year, with a return of -47.43% compared to the S&P 500's 17.14%, and the 3-year return is also negative at -15.71% versus the S&P 500's 70.41%. Overall, the current technical stance is mildly bearish, driven by mixed signals across different indicators and significant underperformance relative to ..."
      },
      {
        "title": "Is Regeneron Pharmaceuticals, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-regeneron-pharmaceuticals-inc-overvalued-or-undervalued-3541915",
        "imagepath": "",
        "date": "2025-09-20 17:39:36",
        "description": "As of 1 August 2025, the valuation grade for Regeneron Pharmaceuticals, Inc. has moved from very attractive to attractive, indicating a shift in perceived value. The company appears to be fairly valued based on its current metrics. Key ratios include a P/E ratio of 16, an EV to EBITDA of 13.64, and a Price to Book Value of 2.29. \n\nIn comparison to peers, Regeneron has a P/E ratio lower than Eli Lilly & Co. at 40.89 and Johnson & Johnson at 26.18, suggesting it may be more attractively priced relative to these competitors. However, it is slightly higher than Merck & Co., Inc. at 15.68, which is also considered attractive. Notably, Regeneron's stock has underperformed against the S&P 500 over the past year, with a return of -47.43% compared to the index's 17.14%, reinforcing the notion that the stock may be fairly valued in light of its recent performance...."
      }
    ],
    "total": 13,
    "sid": "1159823",
    "stock_news_url": "https://www.marketsmojo.com/news/regeneron-pharmaceuticals-inc-1159823"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Regeneron Pharmaceuticals Hits Day Low of $561 Amid Price Pressure

2025-10-09 20:53:00

Regeneron Pharmaceuticals, Inc. faced a challenging trading session on October 8, 2025, with a notable stock price decline. Over the past week, the company has experienced a decrease, contrasting with the S&P 500's performance. Despite recent setbacks, Regeneron maintains a strong market position and demonstrates healthy long-term growth.

Regeneron Pharmaceuticals Experiences Revision in Stock Evaluation Amid Market Challenges

2025-10-07 20:15:14

Regeneron Pharmaceuticals, Inc. has recently revised its evaluation amid changing market conditions. The stock is currently priced at $585.48, with a notable 52-week range. Technical indicators show mixed trends, and the company has faced significant challenges, underperforming compared to the S&P 500 over the past year.

Is Regeneron Pharmaceuticals, Inc. technically bullish or bearish?

2025-10-06 11:58:28

As of 3 October 2025, the technical trend for Regeneron Pharmaceuticals, Inc. has changed from mildly bearish to sideways. The current technical stance is neutral, with mixed indicators influencing the outlook. The weekly MACD is mildly bullish, while the monthly MACD is bearish. The weekly RSI shows no signal, but the monthly RSI is bullish. Bollinger Bands indicate a bullish stance weekly but mildly bearish monthly. Daily moving averages are mildly bearish. The KST is bullish weekly but bearish monthly, and Dow Theory suggests a mildly bullish outlook for both weekly and monthly periods. In terms of performance, Regeneron has underperformed the S&P 500 significantly over the longer term, with a year-to-date return of -15.77% compared to the S&P 500's 14.18%, and a one-year return of -40.86% versus 17.82% for the index....

Is Regeneron Pharmaceuticals, Inc. technically bullish or bearish?

2025-10-05 11:43:18

As of 3 October 2025, the technical trend for Regeneron Pharmaceuticals, Inc. has changed from mildly bearish to sideways. The current stance is neutral, with mixed signals across different indicators. The weekly MACD is mildly bullish, while the monthly MACD is bearish. The RSI shows no signal on the weekly chart but is bullish on the monthly. The Bollinger Bands indicate a bullish trend weekly but mildly bearish monthly. Moving averages are mildly bearish on the daily timeframe. Dow Theory reflects a mildly bullish stance on both weekly and monthly charts. In terms of performance, Regeneron has underperformed the S&P 500 significantly over the longer term, with a year-to-date return of -15.77% compared to the S&P 500's 14.18%, and a one-year return of -40.86% versus 17.82% for the index....

Regeneron Pharmaceuticals Hits Day Low Amid Price Pressure, Closing at $549.40

2025-09-26 14:24:01

Regeneron Pharmaceuticals, Inc. faced a significant decline in stock value, contrasting with the broader market's performance. Over the past year, the company has experienced a substantial decrease, while maintaining strong management efficiency and healthy long-term growth in net sales, reflecting its position in the pharmaceuticals and biotechnology sector.

Regeneron Pharmaceuticals Hits Day Low Amid Price Pressure at $565.53

2025-09-24 13:08:07

Regeneron Pharmaceuticals, Inc. faced a significant stock decline today, reaching an intraday low. Despite this, the company holds a strong market position with a substantial market capitalization and efficient management, evidenced by a notable return on equity. Long-term growth remains positive, supported by healthy net sales increases.

Is Regeneron Pharmaceuticals, Inc. technically bullish or bearish?

2025-09-20 19:06:07

As of 25 August 2025, the technical trend for Regeneron Pharmaceuticals, Inc. has changed from sideways to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD is bearish. The RSI shows no signal on the weekly chart but is bullish on the monthly. Bollinger Bands are bullish weekly but mildly bearish monthly. Daily moving averages are mildly bearish, and the KST is bullish weekly but bearish monthly. Dow Theory indicates a mildly bearish trend on the weekly and no trend on the monthly. In terms of performance, Regeneron has underperformed the S&P 500 significantly over the past year, with a return of -47.43% compared to the S&P 500's 17.14%, and the 3-year return is also negative at -15.71% versus the S&P 500's 70.41%. Overall, the current technical stance is mildly bearish, driven by mixed signals across different indicators and significant underperformance relative to ...

Is Regeneron Pharmaceuticals, Inc. overvalued or undervalued?

2025-09-20 17:39:36

As of 1 August 2025, the valuation grade for Regeneron Pharmaceuticals, Inc. has moved from very attractive to attractive, indicating a shift in perceived value. The company appears to be fairly valued based on its current metrics. Key ratios include a P/E ratio of 16, an EV to EBITDA of 13.64, and a Price to Book Value of 2.29. In comparison to peers, Regeneron has a P/E ratio lower than Eli Lilly & Co. at 40.89 and Johnson & Johnson at 26.18, suggesting it may be more attractively priced relative to these competitors. However, it is slightly higher than Merck & Co., Inc. at 15.68, which is also considered attractive. Notably, Regeneron's stock has underperformed against the S&P 500 over the past year, with a return of -47.43% compared to the index's 17.14%, reinforcing the notion that the stock may be fairly valued in light of its recent performance....

View All News